Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,462 total articles
BridgeBio (BBIO) has fresh Phase 3 data for encaleret in ADH1 and two additional high-impact regulatory reviews on the calendar. The balance of clinical momentum, improving commercial traction for Attruby and a technical setup argue for a long trade. This idea is actionable with entry at $64.50, stop at $54.00 and a primary target of $95.00 over a …
GitLab reported accelerating ARR growth, meaningful SaaS expansion and positive free cash flow while trading at a valuation that still leaves room for upside if enterprise adoption of its DevSecOps platform continues. This trade idea lays out a long entry, targets, stop and the thesis that GitLab can chip away at GitHub's dominance through product-…
Bullish (BLSH) is a beaten-up crypto infrastructure play that is now positioned to become a global leader in tokenized securities after the announced $4.2B Equiniti acquisition and regulatory clears. The deal, combined with improving fundamentals in crypto markets and meaningful short interest, creates a favorable risk/reward for a long entry at cu…
Micron looks attractively positioned after an HBM pricing reset that clears the way for stronger ASP trends later in the cycle. I’m upgrading to a buy and proposing a concrete entry at $95.00 with measured stops and targets across defined horizons. The trade rests on improving pricing for high-margin HBM products, industry supply balance, and Micro…
<p>Airbnb is uniquely placed to monetize the agentic AI wave: it owns a marketplace of supply, a flywheel of user signals, and expanding on-trip services that convert search improvements into higher booking frequency and wallet share. The stock trades at a premium, but fundamentals (strong FCF, high ROE, low leverage) and near-term catalysts justif…
Valero sits on large-scale refining footprint, renewable diesel exposure, and a clean balance sheet. With global refining capacity tight and the Strait of Hormuz disruptions keeping product spreads elevated, VLO's cash generation and valuation make it my top pick into 2027. This trade plan gives precise entry, stop and target levels for a long-term…
Howmet Aerospace (HWM) looks like a buy-the-dip opportunity after recent weakness. The company is riding a commercial-aerospace recovery, reported stronger margins and free cash flow, and raised 2026 revenue guidance. That said, HWM trades at a premium multiple and remains exposed to aerospace cycle and integration risk from recent M&A. This trade …
Virtu Financial combines steady cash flow, a history of earnings beats, and attractive valuation metrics. Recent pullback puts the stock near multi-week support; we view the current price as a tactical buy-the-dip opportunity ahead of Q3 results on 11/05/2026. Enter with a clear stop and a mid- to long-term horizon to capture re-rating and seasonal…
Cabaletta Bio (CABA) has fallen roughly 40% from spring highs to about $1.80 after a pullback in small-cap biotechs. The company still carries promising early clinical data for its rese-cel engineered T cell therapy in autoimmune indications and a reasonable market cap of ~$304M. Technicals show oversold conditions (RSI ~28), heavy short interest a…
Taylor Devices (TAYD) reported a disappointing quarter on 10/02/2026, but the company still sits on a multi-quarter backlog (reported as ~$52.8M in September) and generates solid free cash flow. At a market cap near $194M and trading at $59.94, the stock offers a tactical long with defined risk controls for traders who believe backlog conversion an…
Nebius (NBIS) is the cleaner, higher-growth way to play the AI infrastructure boom versus CoreWeave. The stock is trading off recent highs near $300 and now offers a clear risk-reward: entry around $210, defined stop loss near $182, and a 180-trading-day target near $295. Big caveats remain — capital intensity, execution and financing — but the num…
MidCap Financial (MFIC) is a closed-end manager of senior debt to middle-market companies that currently offers a double-digit distribution yield and trades at a material discount to book. With a thesis that the portfolio is effectively 100% floating-rate, rising short-term rates provide a near-term earnings catalyst that should flow to net investm…
Lincoln National is trading at bargain multiples against improving sector dynamics: P/E ~3.4, P/B ~0.68 and a $7.7B market cap at $40.50. Higher interest rates, strong annuity demand and improving operating metrics make a swing-to-position long the clearest trade. Entry at $40.50, stop $36.00 and target $48.00 balances upside with capital protectio…
CoreWeave faces a contractual covenant that crystallizes in March 2027. The upcoming deadline puts the company in a position where operational execution, access to capital, or renegotiation will determine equity value. My trade: a tactical short sized as a core hedge, entry $12.50, stop $18.75, target $6.25, horizon long term (180 trading days).
ON Semiconductor (ON) combines ~$1.5B in annual free cash flow, a conservative net leverage profile and structural exposure to AI power-delivery and EV electrification. Valuation is not cheap by classic cyclical semiconductor standards (P/E ~47, EV/EBITDA ~16), but operational momentum, management's 12-14% revenue CAGR target and a pending strategi…
TeraWulf's 20-year, $19B lease with Anthropic and the 401 MW Justified Data campus materially shift the company's revenue profile from bitcoin mining to utility-grade AI hosting. The market has priced some of that transition already; I propose a long trade with a strict stop to capture re-rating while limiting downside from execution risk and negat…
Oracle (ORCL) is trading near $137 after a sharp derating from last year's highs. The company still generates strong profitability (ROE ~28%), trades at a mid-teens EV/EBITDA and a P/E of ~22, and sits on strategic AI and renewable-energy initiatives. Negative free cash flow and leverage are valid concerns, but the current price embeds pessimism th…
Generate Biomedicines (GENB) is a clinical-stage generative biology company whose platform aims to design biologics with improved durability and dosing intervals. The stock trades at $13.86 with a $1.78B market cap after a summer run; we believe the market undervalues the commercial premium that longer dosing could command. This trade idea outlines…
Baxter (BAX) has momentum after a strong Q2 print, but the operational disruption and costs tied to the Vantive transition complicate a clear path back to healthy margins. With negative EPS, meaningful leverage and EV/EBITDA above 19x, this is a tactical short against uneven profitability and execution risk. Entry $25.05, stop $28.00, first target …
UroGen is transitioning into a commercial-growth biotech driven by strong Zusduri uptake and stable Jelmyto sales. The stock trades at a high revenue multiple, but near-term revenue cadence and upcoming pipeline readouts create a defined risk/reward for a 180-trading-day trade.
Celsius trades at $28.55 with a $7.18B market cap but generates meaningful free cash flow. Recent suits tied to the Alani Nu brand created a headline-driven selloff. If management executes product reforms and marketing discipline, CELH can regain investor confidence and move materially higher over the next 180 trading days.
Grupo Financiero Galicia (GGAL) looks attractively short right now. Argentina macro volatility, peso sensitivity, and bank-sector risk make a full-throttle recovery unlikely in the next 2-3 months. I prefer a tactical short with strict risk control and a mid-term horizon while watching for stabilization signals that would invalidate the thesis.
Quanta Services (PWR) looks positioned for another leg higher as a record $53.4B backlog and a hyper-growth Technology & Load Centers business (projected +220% to +240% in 2026) push revenue and margin upside. The stock trades at a premium – P/E ~79 and EV/EBITDA ~36.5 – but strong free cash flow ($2.29B trailing) and healthy fundamentals back a tr…
Sana’s fusogen and engineered-cell platform has real scientific milestones and recent partnership momentum. At a $784M market cap and an oversold technical setup, a disciplined long-sized trade can pay off if upcoming collaborations or preclinical readouts push sentiment; downside is large and binary — treat this as a high-risk, event-driven swing.
Marathon Digital (MARA) trades like a busted growth stock while still owning an operating bitcoin-mining machine with tangible production and balance-sheet optionality. The market cap of ~$3.65B and enterprise value of ~$5.65B imply steep discounts to any recovery scenario, but the company carries meaningful leverage, negative cash flow and near-te…
